Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq: FBLG) announced Nasdaq has confirmed the company meets all applicable continued-listing criteria, including the $2.5 million stockholders' equity and the $1.00 bid price requirements. The company resolved its compliance issues but will remain under one-year monitoring for both metrics.
FibroBiologics is a clinical-stage biotech with 270+ patents issued and pending; its common stock will continue trading on Nasdaq under FBLG.
FibroBiologics (Nasdaq: FBLG) presented preclinical data on April 10, 2026 showing a proprietary thymic organoid platform that restored multiple thymic functions in immunodeficient mice.
Organoids generated diverse, functional T cell lineages, maintained key thymic gene expression, were cryopreservable and injectable, and slowed tumor growth in a melanoma model.
FibroBiologics (NASDAQ: FBLG) closed a best-efforts public offering on April 2, 2026, selling 2,272,728 shares and warrants to purchase up to 2,272,728 shares at a combined public offering price of $1.32 per share and warrant.
The offering generated approximately $3 million gross proceeds before fees; the Warrants carry a $1.32 exercise price and, if fully exercised, could provide an additional ~$3 million. Warrants become exercisable upon stockholder approval and expire five years after that date.
FibroBiologics (NASDAQ: FBLG) priced a best-efforts public offering of 2,272,728 common shares and warrants at a combined price of $1.32 each, expected to raise approximately $3.0 million gross, before fees. Warrants cover up to 2,272,728 shares at a $1.32 exercise price.
The offering closing is expected on or about April 2, 2026, subject to customary conditions and stockholder approval for warrant exercises; potential additional gross proceeds from full warrant exercise equal approximately $3.0 million. Net proceeds are for working capital and general corporate purposes.
FibroBiologics (Nasdaq: FBLG) announced completion of manufacturing the first batch of its proprietary CYWC628 drug product to support planned first‑in‑human trials.
The product was manufactured under FDA CGMP standards and will be released after required safety and quality testing. The company plans a Phase 1/2 diabetic foot ulcer trial in the first half of 2026.
FibroBiologics (Nasdaq: FBLG) announced a 1-for-20 reverse stock split expected to take effect at 12:01 a.m. ET on March 30, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
Post-split outstanding shares will decrease from 70,256,883 to approximately 3,512,845, fractional shares rounded up, and trading will continue under the ticker FBLG.
FibroBiologics (Nasdaq: FBLG) announced expansion of its wound care platform into acute and chronic burn treatment using its proprietary fibroblast spheroid therapy CYWC628.
In preclinical burn models, CYWC628 increased tissue IL-10 nearly four-fold and reduced IL-1B, suggesting faster, higher-quality healing; company plans to advance toward clinical development and integrate burn work into its wound care strategy.
The release cites a global burn care market of $2.55B today, growing to $3.35B by 2030.
FibroBiologics (Nasdaq: FBLG) completed onboarding of clinical sites for its Phase 1/2 trial of CYWC628, an allogeneic fibroblast spheroid topical therapy for refractory diabetic foot ulcers.
The prospective, multicenter, open-label study will test low and high doses plus standard of care for up to 12 weeks, with an interim analysis after a predefined cohort completes six weeks. Southern Star Research will manage trial operations across APAC.
FibroBiologics (Nasdaq: FBLG) announced issuance of U.S. Patent No. 12,544,407 B2, dated February 10, 2026, covering fibroblast cell therapy for osteoporosis. The patent claims systemic and local administration, modified/dedifferentiated fibroblasts (OCT4, NANOG, SOX2), recombinant CXCR4/hTERT, marker-selected cells, and combination use with anti-inflammatory agents.
This issuance strengthens the company’s intellectual property in regenerative medicine and bone disorders and supports its strategy to develop proprietary fibroblast therapies addressing osteoporosis and related bone diseases.
FibroBiologics (Nasdaq: FBLG) announced its Founder and CEO, Pete O’Heeron, will present at the BIO Investment & Growth Summit March 2-3, 2026, at Eden Roc, Miami Beach. The company presentation is scheduled for 10:15 a.m. ET on Monday, March 2, and management will hold one-on-one meetings during the event.
Investors can obtain more information via the company website or by contacting info@fibrobiologics.com; social channels include LinkedIn, YouTube, Facebook and X.